Literature DB >> 7594687

Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells.

C B Louise1, T G Obrig.   

Abstract

In Escherichia coli O157:H7 foodborne infections of humans, the Shiga-like toxins (SLTs) are thought to be the cause of life-threatening vascular complications, including acute renal disease known as hemolytic uremic syndrome or HUS. As virtually all E. coli O157:H7 isolates from HUS patients produce SLT-II (vs. SLT-I), the possible preferential interaction of SLT-II with human renal microvascular endothelial cells (HRMEC), the putative target of the SLTs in the development of HUS, was studied. SLT-II was 1000 times more potent a cytotoxic agent than SLT-I toward HRMEC. Toxin binding studies showed that this occurred although HRMEC could bind 10 times more SLT-I than SLT-II. This preferential action of SLT-II was specific for renal endothelial cells, as human umbilical vein endothelial cells were almost equally affected by SLT-I and SLT-II.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594687     DOI: 10.1093/infdis/172.5.1397

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  61 in total

1.  Inhibition of neutrophil apoptosis by verotoxin 2 derived from Escherichia coli O157:H7.

Authors:  J Liu; T Akahoshi; T Sasahana; H Kitasato; R Namai; T Sasaki; M Inoue; H Kondo
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

2.  Serum amyloid P component binding to Shiga toxin 2 requires both a subunit and B pentamer.

Authors:  Paola Marcato; Kathleen Vander Helm; George L Mulvey; Glen D Armstrong
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

3.  Genetic typing of shiga toxin 2 variants of Escherichia coli by PCR-restriction fragment length polymorphism analysis.

Authors:  Liesbet De Baets; Imme Van der Taelen; Marina De Filette; Denis Piérard; Lesley Allison; Henri De Greve; Jean-Pierre Hernalsteens; Hein Imberechts
Journal:  Appl Environ Microbiol       Date:  2004-10       Impact factor: 4.792

4.  Strong association between shiga toxin-producing Escherichia coli O157 and virulence genes stx2 and eae as possible explanation for predominance of serogroup O157 in patients with haemolytic uraemic syndrome.

Authors:  D Werber; A Fruth; U Buchholz; R Prager; M H Kramer; A Ammon; H Tschäpe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-11-12       Impact factor: 3.267

5.  Non-O157 verotoxigenic Escherichia coli and beef: a Canadian perspective.

Authors:  Alexander Gill; Colin O Gill
Journal:  Can J Vet Res       Date:  2010-07       Impact factor: 1.310

6.  Association of virulence genotype with phylogenetic background in comparison to different seropathotypes of Shiga toxin-producing Escherichia coli isolates.

Authors:  Jean Pierre Girardeau; Alessandra Dalmasso; Yolande Bertin; Christian Ducrot; Séverine Bord; Valérie Livrelli; Christine Vernozy-Rozand; Christine Martin
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

Review 7.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Shigatoxin-1 binding and receptor expression in human kidneys do not change with age.

Authors:  Zuhal Ergonul; Frederic Clayton; Agnes B Fogo; Donald E Kohan
Journal:  Pediatr Nephrol       Date:  2003-02-07       Impact factor: 3.714

9.  Sensitivities and specificities of premier E. coli O157 and premier EHEC enzyme immunoassays for diagnosis of infection with verotxin (Shiga-like toxin)-producing Escherichia coli. The SYNSORB Pk Study investigators.

Authors:  A M Mackenzie; P Lebel; E Orrbine; P C Rowe; L Hyde; F Chan; W Johnson; P N McLaine
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

10.  Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.

Authors:  Richard L Siegler; Tom G Obrig; Theodore J Pysher; Vernon L Tesh; Nathaniel D Denkers; Fletcher B Taylor
Journal:  Pediatr Nephrol       Date:  2003-01-10       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.